SCHEMBL337138

SCHEMBL337138

CN(C(=O)O)c1ncc(-c2nc(N3CCOCC3)c3nc(Cl)n(CC4CCOC4)c3n2)cn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 16/20 0.46
PIK3CA P42336 6/20 0.46
PIK3R1 P27986 3/20 0.46
PIK3CD O00329 3/20 0.43
HDAC3 O15379 3/20 0.43
HDAC4 P56524 3/20 0.43
HDAC7 Q8WUI4 3/20 0.43
HDAC2 Q92769 3/20 0.43
HDAC10 Q969S8 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HDAC9 Q9UKV0 3/20 0.43
HDAC5 Q9UQL6 3/20 0.43
NCOR2 Q9Y618 3/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336743 0.94 HDAC1 (0.48) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL799284 0.90 HDAC1 (0.43) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL2843236 0.86 PIK3CA (0.43) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL799462 0.86 PIK3CA (0.42) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
Bicarbonate SCHEMBL2869577 0.85 PIK3CA (0.42) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL16473604 0.85 PIK3CA (0.41) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
Bicarbonate SCHEMBL363863 0.85 PIK3CA (0.43) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL2869582 0.84 PIK3CA (0.49) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL337137 0.84 PIK3CA (0.40) HDAC1PIK3CAPIK3R1PIK3CDHDAC3
SCHEMBL336882 0.84 PIK3CA (0.54) HDAC1PIK3CAPIK3R1PIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2336132-B1 MORPHOLINOPURINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2014-01-01 EP disclosed
US-8309546-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-13 US disclosed
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-22 US disclosed
US-8097622-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-17 US disclosed
EP-2336132-A1 MORPHOLINOPURINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES MTOR, RICTOR, PIK3R1 HDAC1 385/4885PIK3CA 22/4885PIK3R1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.